Effects of recombinant human growth hormone on protein turnover in the fasting and fed state in adolescents with Crohn disease

Research output: Contribution to journalArticle

Abstract

The primary purpose of this study was to test whether recombinant human growth hormone (rhGH) supplementation would enhance protein synthesis and accretion of lean body mass. Eight adolescents (six males and two females; 17.2±2.6 years; age range, 13.7-21.2 years) participated in a randomized double-blind placebo-controlled cross-over trial of rhGH. We employed stable isotopes to measure proteolysis and protein synthesis during fasting and fed conditions during two 6-month treatment conditions. We also measured bone mineral density (BMD), markers of bone turnover, and body composition. Whole-body proteolysis, phenylalanine catabolism, and protein synthesis did not differ during treatment with rhGH vs. placebo. Enteral nutrition suppressed proteolysis and increased protein synthesis similarly during placebo and rhGH treatments. We conclude that rhGH is unlikely to provide sufficient metabolic benefit to warrant its use as an adjunct treatment in clinically stable adolescents with Crohn disease. A high prevalence of vitamin D deficiency and suboptimal BMD existed, which deserves further investigation and clinical attention.

Original languageEnglish
Pages (from-to)633-640
Number of pages8
JournalJournal of Pediatric Endocrinology and Metabolism
Volume24
Issue number9-10
DOIs
StatePublished - Oct 2011

Fingerprint

Human Growth Hormone
Crohn Disease
Growth Hormone
Fasting
Proteolysis
Placebos
Proteins
Bone Density
Vitamin D Deficiency
Bone Remodeling
Enteral Nutrition
Therapeutics
Body Composition
Phenylalanine
Isotopes
Cross-Over Studies

Keywords

  • Adolescents
  • Crohn disease
  • Inflammatory bowel disease
  • Protein metabolism
  • Protein turnover
  • Recombinant human growth hormone

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

@article{de833363b171427baef7e96b906da0e2,
title = "Effects of recombinant human growth hormone on protein turnover in the fasting and fed state in adolescents with Crohn disease",
abstract = "The primary purpose of this study was to test whether recombinant human growth hormone (rhGH) supplementation would enhance protein synthesis and accretion of lean body mass. Eight adolescents (six males and two females; 17.2±2.6 years; age range, 13.7-21.2 years) participated in a randomized double-blind placebo-controlled cross-over trial of rhGH. We employed stable isotopes to measure proteolysis and protein synthesis during fasting and fed conditions during two 6-month treatment conditions. We also measured bone mineral density (BMD), markers of bone turnover, and body composition. Whole-body proteolysis, phenylalanine catabolism, and protein synthesis did not differ during treatment with rhGH vs. placebo. Enteral nutrition suppressed proteolysis and increased protein synthesis similarly during placebo and rhGH treatments. We conclude that rhGH is unlikely to provide sufficient metabolic benefit to warrant its use as an adjunct treatment in clinically stable adolescents with Crohn disease. A high prevalence of vitamin D deficiency and suboptimal BMD existed, which deserves further investigation and clinical attention.",
keywords = "Adolescents, Crohn disease, Inflammatory bowel disease, Protein metabolism, Protein turnover, Recombinant human growth hormone",
author = "Tamara Hannon and Linda DiMeglio and Marian Pfefferkorn and Aaron Carroll and Scott Denne",
year = "2011",
month = "10",
doi = "10.1515/JPEM.2011.308",
language = "English",
volume = "24",
pages = "633--640",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "9-10",

}

TY - JOUR

T1 - Effects of recombinant human growth hormone on protein turnover in the fasting and fed state in adolescents with Crohn disease

AU - Hannon, Tamara

AU - DiMeglio, Linda

AU - Pfefferkorn, Marian

AU - Carroll, Aaron

AU - Denne, Scott

PY - 2011/10

Y1 - 2011/10

N2 - The primary purpose of this study was to test whether recombinant human growth hormone (rhGH) supplementation would enhance protein synthesis and accretion of lean body mass. Eight adolescents (six males and two females; 17.2±2.6 years; age range, 13.7-21.2 years) participated in a randomized double-blind placebo-controlled cross-over trial of rhGH. We employed stable isotopes to measure proteolysis and protein synthesis during fasting and fed conditions during two 6-month treatment conditions. We also measured bone mineral density (BMD), markers of bone turnover, and body composition. Whole-body proteolysis, phenylalanine catabolism, and protein synthesis did not differ during treatment with rhGH vs. placebo. Enteral nutrition suppressed proteolysis and increased protein synthesis similarly during placebo and rhGH treatments. We conclude that rhGH is unlikely to provide sufficient metabolic benefit to warrant its use as an adjunct treatment in clinically stable adolescents with Crohn disease. A high prevalence of vitamin D deficiency and suboptimal BMD existed, which deserves further investigation and clinical attention.

AB - The primary purpose of this study was to test whether recombinant human growth hormone (rhGH) supplementation would enhance protein synthesis and accretion of lean body mass. Eight adolescents (six males and two females; 17.2±2.6 years; age range, 13.7-21.2 years) participated in a randomized double-blind placebo-controlled cross-over trial of rhGH. We employed stable isotopes to measure proteolysis and protein synthesis during fasting and fed conditions during two 6-month treatment conditions. We also measured bone mineral density (BMD), markers of bone turnover, and body composition. Whole-body proteolysis, phenylalanine catabolism, and protein synthesis did not differ during treatment with rhGH vs. placebo. Enteral nutrition suppressed proteolysis and increased protein synthesis similarly during placebo and rhGH treatments. We conclude that rhGH is unlikely to provide sufficient metabolic benefit to warrant its use as an adjunct treatment in clinically stable adolescents with Crohn disease. A high prevalence of vitamin D deficiency and suboptimal BMD existed, which deserves further investigation and clinical attention.

KW - Adolescents

KW - Crohn disease

KW - Inflammatory bowel disease

KW - Protein metabolism

KW - Protein turnover

KW - Recombinant human growth hormone

UR - http://www.scopus.com/inward/record.url?scp=80054080112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054080112&partnerID=8YFLogxK

U2 - 10.1515/JPEM.2011.308

DO - 10.1515/JPEM.2011.308

M3 - Article

VL - 24

SP - 633

EP - 640

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 9-10

ER -